A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
• The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.
Locations
Other Locations
China
The Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
xiaojuan lai
lai_xiaojuan@vcarepharmatech.com
15358160458
Time Frame
Start Date: 2025-10-31
Estimated Completion Date: 2027-08-30
Participants
Target number of participants: 120
Treatments
Experimental: VC005 Tablets Low Dose groups
Experimental: VC005 Tablets High Dose groups
Placebo_comparator: VC005 Tablets Placebo groups
Related Therapeutic Areas
Sponsors
Leads: Jiangsu vcare pharmaceutical technology co., LTD